Jenny Ruiz
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jenny Ruiz has a total of 89 co-authors. Here are the top co-authors by number of shared publications:
Alix E. Seif
Children's Hospital of Philadelphia Philadelphia Pennsylvania USA
4 shared publicationsRichard Aplenc
Children's Hospital of Philadelphia Philadelphia Pennsylvania USA
4 shared publicationsBrian T. Fisher
Department of Biostatistics, Epidemioloy and Informatics Perelman School of Medicine, University of Pennsylvania Philadelphia Pennsylvania USA
3 shared publications- Lena E. Winestone
Division of Pediatric Allergy, Immunology, and Bone Marrow Transplantation, University of California San Francisco, San Francisco, CA
3 shared publications Yimei Li
Department of Biostatistics, Epidemioloy and Informatics Perelman School of Medicine, University of Pennsylvania Philadelphia Pennsylvania USA
3 shared publications- Alix E. Seif
Division of Oncology, Children’s Hospital of Philadelphia, Philadelphia, USA
2 shared publications
Latest Publications
- Open Access
- 1 October 2026
- Published by Elsevier in Academic Pediatrics
- Vol. 26 (8) , 103483
Treat Us Like Humans: Lived Experience Solutions to Improve Health Care for Multiply Marginalized Children with Disabilities
- 1 October 2026
- Published by Elsevier in Academic Pediatrics
- Vol. 26 (8) , 103483
Open AccessTreat Us Like Humans: Lived Experience Solutions to Improve Health Care for Multiply Marginalized Children with Disabilities
- Open Access
- 28 September 2026
- Published by Wiley in Pediatric Blood & Cancer
Language, Culture, and Cancer: Qualitative Insights Into Communication Disparities Among Spanish‐Speaking Caregivers of Children With Cancer
Background: Latino children are projected to make up nearly one‐third of United States (US) children by 2060, and many of their caregivers speak Spanish. Prior survey research has documented communication difficulties for Spanish‐speaking caregivers of children with cancer, but contemporary qualitative data are limited. We sought to understand the communication experiences of Spanish‐speaking caregivers during a new childhood cancer diagnosis and elicit recommendations for improving family‐centered diagnostic communication. Methods: We conducted semi‐structured qualitative interviews in Spanish with adult Spanish‐speaking caregivers present during the initial oncology diagnosis conversation for a child diagnosed within the prior 10 years. Participants were recruited from two US pediatric centers using purposeful sampling. Bilingual interviewers conducted interviews from July 2024 to May 2025. Transcripts were analyzed using inductive qualitative content analysis by two independent bilingual coders, with iterative codebook development and constant comparison until thematic saturation. Results: Eleven mothers participated, all born outside the US; most children had hematologic malignancies. Five themes were identified as follows: (1) interpreter access and quality impacted understanding; (2) strong emotional responses to diagnosis, sometimes framed by cultural beliefs; (3) difficulty voicing concerns due to language differences; (4) experiencing connection when clinicians took time to communicate the diagnosis; and (5) recommendations, including more bilingual clinicians, in‐person professional interpreters, plain‐language explanations, and cultural humility training. Conclusions: Meaningful communication with Spanish‐speaking families at diagnosis requires systems‐level investment in qualified interpreters and bilingual clinicians, clinician behaviors that invite questions and validate emotion, and culturally responsive care.
- 28 September 2026
- Published by Wiley in Pediatric Blood & Cancer
Open AccessLanguage, Culture, and Cancer: Qualitative Insights Into Communication Disparities Among Spanish‐Speaking Caregivers of Children With Cancer
Background: Latino children are projected to make up nearly one‐third of United States (US) children by 2060, and many of their caregivers speak Spanish. Prior survey research has documented communication difficulties for Spanish‐speaking caregivers of children with cancer, but contemporary qualitative data are limited. We sought to understand the communication experiences of Spanish‐speaking caregivers during a new childhood cancer diagnosis and elicit recommendations for improving family‐centered diagnostic communication. Methods: We conducted semi‐structured qualitative interviews in Spanish with adult Spanish‐speaking caregivers present during the initial oncology diagnosis conversation for a child diagnosed within the prior 10 years. Participants were recruited from two US pediatric centers using purposeful sampling. Bilingual interviewers conducted interviews from July 2024 to May 2025. Transcripts were analyzed using inductive qualitative content analysis by two independent bilingual coders, with iterative codebook development and constant comparison until thematic saturation. Results: Eleven mothers participated, all born outside the US; most children had hematologic malignancies. Five themes were identified as follows: (1) interpreter access and quality impacted understanding; (2) strong emotional responses to diagnosis, sometimes framed by cultural beliefs; (3) difficulty voicing concerns due to language differences; (4) experiencing connection when clinicians took time to communicate the diagnosis; and (5) recommendations, including more bilingual clinicians, in‐person professional interpreters, plain‐language explanations, and cultural humility training. Conclusions: Meaningful communication with Spanish‐speaking families at diagnosis requires systems‐level investment in qualified interpreters and bilingual clinicians, clinician behaviors that invite questions and validate emotion, and culturally responsive care.
- Open Access
- 14 January 2025
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 72 (4) , e31521
Achieving Language Justice in Pediatric Hematology‐Oncology: A Multinational Perspective for Language‐Concordant Equitable Patient‐ and Family‐Centered Care and Research Inclusion
Language‐discordant healthcare encounters—when the patient/caregiver and clinician are not able to communicate directly in the patient's/caregiver's preferred language—are associated with worse quality of care, increased adverse events, and research exclusion. Here, we describe the current state of language justice in clinical practice and research in the United States, Canada, and Spain, discuss the role of social determinants of health and language in patient safety and health outcomes, and review an example of culturally and linguistically concordant interventions to increase research participation. We close with practical and global strategies to increase multilingual research participation and to provide equitable patient‐ and family‐centered care in pediatric hematology‐oncology.
- 14 January 2025
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 72 (4) , e31521
Open AccessAchieving Language Justice in Pediatric Hematology‐Oncology: A Multinational Perspective for Language‐Concordant Equitable Patient‐ and Family‐Centered Care and Research Inclusion
Language‐discordant healthcare encounters—when the patient/caregiver and clinician are not able to communicate directly in the patient's/caregiver's preferred language—are associated with worse quality of care, increased adverse events, and research exclusion. Here, we describe the current state of language justice in clinical practice and research in the United States, Canada, and Spain, discuss the role of social determinants of health and language in patient safety and health outcomes, and review an example of culturally and linguistically concordant interventions to increase research participation. We close with practical and global strategies to increase multilingual research participation and to provide equitable patient‐ and family‐centered care in pediatric hematology‐oncology.
- 25 September 2024
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 71 (12) , e31338
The impact of language discordance on pediatric cancer care outcomes: A systematic review
Language discordance between clinicians and families in pediatrics has been associated with adverse events and lower quality of care. We aimed to summarize the existing literature evaluating the impact of language discordance among healthcare professionals and families within pediatric oncology by conducting a systematic review. Of 8364 studies, 43 studies met eligibility for inclusion in this review. These studies highlight the impact of language discordance on pediatric cancer care outcomes, including communication challenges, obstacles to research participation, and potentially higher risk disease features at presentation. Healthcare professionals endorsed inconsistent professional interpreter use and lack of formal training on communicating via interpreters. Interventions to address barriers to language‐appropriate care are sparse. Further research is warranted to design and implement interventions promoting language justice and provision of high‐quality, equitable pediatric cancer care for all families.
- 25 September 2024
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 71 (12) , e31338
The impact of language discordance on pediatric cancer care outcomes: A systematic review
Language discordance between clinicians and families in pediatrics has been associated with adverse events and lower quality of care. We aimed to summarize the existing literature evaluating the impact of language discordance among healthcare professionals and families within pediatric oncology by conducting a systematic review. Of 8364 studies, 43 studies met eligibility for inclusion in this review. These studies highlight the impact of language discordance on pediatric cancer care outcomes, including communication challenges, obstacles to research participation, and potentially higher risk disease features at presentation. Healthcare professionals endorsed inconsistent professional interpreter use and lack of formal training on communicating via interpreters. Interventions to address barriers to language‐appropriate care are sparse. Further research is warranted to design and implement interventions promoting language justice and provision of high‐quality, equitable pediatric cancer care for all families.
- 5 September 2024
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 71 (11) , e31321
Multilevel challenges to equitable inclusion of children in trials when parents use languages other than English: A qualitative report from Children's Oncology Group's Diversity and Health Disparities Committee Language Equity Working Group
Background: Increasing representation in clinical trials is a priority for the National Cancer Institute and Children's Oncology Group (COG). Our survey of COG‐affiliated institutions revealed that many sites have insufficient processes and resources to enroll children whose parents use languages other than English (LOE). We describe reported barriers and facilitators to enrolling children in clinical trials when parents use LOE and propose opportunities for improvement.Procedures: We sent a 20‐item survey to COG‐affiliated institutions. Five items allowed respondents to expand on replies to questions about (a) local institutional review board (IRB) requirements regarding translation of consent documents, (b) contributors to provider discomfort consenting parents who use LOE, (c) available language services and resources, and (d) barriers to enrolling children whose parents use LOE or offer ideas about approaches to improvements. Two pairs of researchers independently coded free‐text responses and compared results for concordance.Results: A total of 139 (N = 230; 60%) institutions returned the survey. Respondents were mainly physician principal investigators (n = 79/139; 57%) at the United States sites (n = 118/139; 85%) serving less than 100 newly diagnosed children per year (n = 99/139, 71%). They described challenges at multiple levels. Proposed approaches to improvements included centralized provision of translated materials and video educational materials in various languages, and collaborating with IRBs on regulatory processes that protect families and facilitate equitable clinical trial access.Conclusions: Clinical trial consortia, such as COG, face challenges in enrolling representative samples. Further research is required to design and implement multilevel interventions to ensure equitable access for all, regardless of language used, and mitigate disparate research participation.
- 5 September 2024
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 71 (11) , e31321
Multilevel challenges to equitable inclusion of children in trials when parents use languages other than English: A qualitative report from Children's Oncology Group's Diversity and Health Disparities Committee Language Equity Working Group
Background: Increasing representation in clinical trials is a priority for the National Cancer Institute and Children's Oncology Group (COG). Our survey of COG‐affiliated institutions revealed that many sites have insufficient processes and resources to enroll children whose parents use languages other than English (LOE). We describe reported barriers and facilitators to enrolling children in clinical trials when parents use LOE and propose opportunities for improvement.Procedures: We sent a 20‐item survey to COG‐affiliated institutions. Five items allowed respondents to expand on replies to questions about (a) local institutional review board (IRB) requirements regarding translation of consent documents, (b) contributors to provider discomfort consenting parents who use LOE, (c) available language services and resources, and (d) barriers to enrolling children whose parents use LOE or offer ideas about approaches to improvements. Two pairs of researchers independently coded free‐text responses and compared results for concordance.Results: A total of 139 (N = 230; 60%) institutions returned the survey. Respondents were mainly physician principal investigators (n = 79/139; 57%) at the United States sites (n = 118/139; 85%) serving less than 100 newly diagnosed children per year (n = 99/139, 71%). They described challenges at multiple levels. Proposed approaches to improvements included centralized provision of translated materials and video educational materials in various languages, and collaborating with IRBs on regulatory processes that protect families and facilitate equitable clinical trial access.Conclusions: Clinical trial consortia, such as COG, face challenges in enrolling representative samples. Further research is required to design and implement multilevel interventions to ensure equitable access for all, regardless of language used, and mitigate disparate research participation.
- Open Access
- 18 June 2024
- Published by Oxford University Press (OUP) in JNCI Cancer Spectrum
- Vol. 8 (4)
Clinical trial recruitment of people who speak languages other than English: a Children’s Oncology Group report
Background: Persons who speak languages other than English are underrepresented in clinical trials, likely in part because of inadequate multilevel resources. We conducted a survey of institutions affiliated with the Children’s Oncology Group (COG) to characterize current research recruitment practices and resources regarding translation and interpretation services. Methods: In October 2022, a 20-item survey was distributed electronically to institutions affiliated with COG to assess consent practices and resources for recruiting participants who speak languages other than English to COG trials. Descriptive statistics were used to summarize responses; responses were compared by institution size and type as well as respondent role. Results: The survey was sent to 230 institutions, and the response rate was 60% (n = 139). In total, 60% (n = 83) of those respondents had access to short-form consent forms. Full consent form translation was required at 50% of institutions, and 12% of institutional review boards restricted use of centrally translated consent forms. Forty-six percent (n = 64) of institutions reported insufficient funding to support translation costs; 19% (n = 26) had access to no-cost translation services. Forty-four percent (n = 61) were required to use in-person interpreters for consent discussions; the most frequently cited barrier (56%) to obtaining consent was lack of available in-person interpreters. Forty-seven percent (n = 65) reported that recruiting persons who speak languages other than English to clinical trials was somewhat or very difficult. Conclusions: Institutions affiliated with COG face resource-specific challenges that impede recruitment of participants who speak languages other than English for clinical trials. These findings indicate an urgent need to identify strategies aimed at reducing recruitment barriers to ensure equitable access to clinical trials.
- 18 June 2024
- Published by Oxford University Press (OUP) in JNCI Cancer Spectrum
- Vol. 8 (4)
Open AccessClinical trial recruitment of people who speak languages other than English: a Children’s Oncology Group report
Background: Persons who speak languages other than English are underrepresented in clinical trials, likely in part because of inadequate multilevel resources. We conducted a survey of institutions affiliated with the Children’s Oncology Group (COG) to characterize current research recruitment practices and resources regarding translation and interpretation services. Methods: In October 2022, a 20-item survey was distributed electronically to institutions affiliated with COG to assess consent practices and resources for recruiting participants who speak languages other than English to COG trials. Descriptive statistics were used to summarize responses; responses were compared by institution size and type as well as respondent role. Results: The survey was sent to 230 institutions, and the response rate was 60% (n = 139). In total, 60% (n = 83) of those respondents had access to short-form consent forms. Full consent form translation was required at 50% of institutions, and 12% of institutional review boards restricted use of centrally translated consent forms. Forty-six percent (n = 64) of institutions reported insufficient funding to support translation costs; 19% (n = 26) had access to no-cost translation services. Forty-four percent (n = 61) were required to use in-person interpreters for consent discussions; the most frequently cited barrier (56%) to obtaining consent was lack of available in-person interpreters. Forty-seven percent (n = 65) reported that recruiting persons who speak languages other than English to clinical trials was somewhat or very difficult. Conclusions: Institutions affiliated with COG face resource-specific challenges that impede recruitment of participants who speak languages other than English for clinical trials. These findings indicate an urgent need to identify strategies aimed at reducing recruitment barriers to ensure equitable access to clinical trials.
- Open Access
- 26 February 2024
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 71 (5) , e30925
Absolute neutrophil count clinical trial eligibility criteria for pediatric oncology phase I and phase I/II trials by sponsorship
Normal absolute neutrophil count (ANC) variations, as seen with Duffy‐null associated neutrophil count (DANC), are not accounted for in trial eligibility, which may contribute to racial enrollment disparities. We describe ANC eligibility for pediatric oncology phase I/II clinical trials according to primary sponsorship from 2010 to 2023 using ClinicalTrials.gov. Out of 438 trials, 20% were industry‐sponsored. Total 17% of trials required ANC ≥1500 cells/μL for enrollment; however, industry‐sponsored trials were significantly more likely to require ANC ≥1500 cells/μL than non‐industry‐sponsored trials (odds ratio 2.53, 95% confidence interval: 1.39–4.62; p < .001). These data suggest laboratory exclusion criteria are one possible mechanism for pediatric clinical trial enrollment disparities.
- 26 February 2024
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 71 (5) , e30925
Open AccessAbsolute neutrophil count clinical trial eligibility criteria for pediatric oncology phase I and phase I/II trials by sponsorship
Normal absolute neutrophil count (ANC) variations, as seen with Duffy‐null associated neutrophil count (DANC), are not accounted for in trial eligibility, which may contribute to racial enrollment disparities. We describe ANC eligibility for pediatric oncology phase I/II clinical trials according to primary sponsorship from 2010 to 2023 using ClinicalTrials.gov. Out of 438 trials, 20% were industry‐sponsored. Total 17% of trials required ANC ≥1500 cells/μL for enrollment; however, industry‐sponsored trials were significantly more likely to require ANC ≥1500 cells/μL than non‐industry‐sponsored trials (odds ratio 2.53, 95% confidence interval: 1.39–4.62; p < .001). These data suggest laboratory exclusion criteria are one possible mechanism for pediatric clinical trial enrollment disparities.
- 5 February 2024
- Published by American Medical Association (AMA) in JAMA Network Open
- Vol. 7 (2) , e2355679
Chemotherapy Delays Due to SARS-CoV-2 Infection in Children With Leukemia or Lymphoma
Studies, although limited, have shown conflicting findings in the clinical presentation and outcomes of COVID-19 in children with cancer. Hashmi et al focused o
- 5 February 2024
- Published by American Medical Association (AMA) in JAMA Network Open
- Vol. 7 (2) , e2355679
Chemotherapy Delays Due to SARS-CoV-2 Infection in Children With Leukemia or Lymphoma
Studies, although limited, have shown conflicting findings in the clinical presentation and outcomes of COVID-19 in children with cancer. Hashmi et al focused o
- 8 January 2024
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 71 (3) , e30858
Applying machine learning to identify pediatric patients with newly diagnosed acute lymphoblastic leukemia using administrative data
Case identification in administrative databases is challenging as diagnosis codes alone are not adequate for case ascertainment. We utilized machine learning (ML) to efficiently identify pediatric patients with newly diagnosed acute lymphoblastic leukemia. We tested nine ML models and validated the best model internally and externally. The optimal model had 97% positive predictive value (PPV) and 99% sensitivity in internal validation; 94% PPV and 82% sensitivity in external validation. Our ML model identified a large cohort of 21,044 patients, demonstrating an efficient approach for cohort assembly and enhancing the usability of administrative data.
- 8 January 2024
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 71 (3) , e30858
Applying machine learning to identify pediatric patients with newly diagnosed acute lymphoblastic leukemia using administrative data
Case identification in administrative databases is challenging as diagnosis codes alone are not adequate for case ascertainment. We utilized machine learning (ML) to efficiently identify pediatric patients with newly diagnosed acute lymphoblastic leukemia. We tested nine ML models and validated the best model internally and externally. The optimal model had 97% positive predictive value (PPV) and 99% sensitivity in internal validation; 94% PPV and 82% sensitivity in external validation. Our ML model identified a large cohort of 21,044 patients, demonstrating an efficient approach for cohort assembly and enhancing the usability of administrative data.
- 1 December 2023
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 41 (34) , 5324-5327
Buenos Días: A Letter to My Patient's Mother
@JennyRuizMD shares a poignant story of peds oncology immigrant family, #SDOH, & similarities to her own family’s experience. #LatinasinMedicine
- 1 December 2023
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 41 (34) , 5324-5327
Buenos Días: A Letter to My Patient's Mother
@JennyRuizMD shares a poignant story of peds oncology immigrant family, #SDOH, & similarities to her own family’s experience. #LatinasinMedicine